Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.

The user experienced hair regrowth after 9 months using 0.5 mg dutasteride and 2.5 mg oral minoxidil, with initial shedding that reversed by the third month. The user reported no side effects and felt good overall.

The user has been using finasteride for 10 months with no significant regrowth but no further hair loss and is considering adding oral minoxidil despite concerns about side effects. Other users suggest combining finasteride with minoxidil for better results, as finasteride prevents further hair loss while minoxidil aids regrowth.

The user reports significant hair regrowth after 10 months using 1 mg oral finasteride daily and a 1.25 mm derma stamp bi-weekly with rosemary and jojoba oil. Other users commend the progress and inquire about the routine and side effects.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The user shared progress pictures showing hair growth after 9 months of using 1 mg oral finasteride, 2.5 mg oral minoxidil (recently increased to 5 mg), and 2% ketoconazole shampoo. Users discussed the effectiveness and side effects of these treatments, with some suggesting alternative methods and cautioning about minoxidil dosage.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

A user shared their 9-year experience with finasteride and 3 years with oral minoxidil, noting positive hair maintenance and regrowth without significant side effects. They are considering a hair transplant but are generally satisfied with their current hair condition.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.

The conversation discusses using RU58841 for hair loss, with OP applying a 5% premixed solution from Receptorchem daily. Users express skepticism about the rapid results and inquire about other treatments and costs.

The user is using topical Minoxidil, finasteride, dermastamp, and Nizoral shampoo for hair loss and is considering continuing the treatment. Suggestions include possibly switching to dutasteride, oral Minoxidil, adding tretinoin, and considering a hair transplant for better results.

Finasteride significantly improved the user's hair, with no noticeable side effects except mild initial testicle pain. Minoxidil was used but only showed results after starting Finasteride.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.

The user experienced significant hair regrowth and increased confidence after 8 months of using 1mg finasteride daily and 6% topical minoxidil once a day. They reported no side effects and are considering microneedling and possibly testosterone replacement therapy if needed.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.